The U.S. Food and Drug Administration has approved a new drug for ... causes of disability worldwide, the FDA reports. Individuals with this disease have a greater risk of dying young, and nearly ...

The FDA has approved Alnylam’s gene silencing drug ... As the kidney function worsens, oxalate can build up and damage other organs including the heart, bones and eyes. The disease is also ...

Kisqali, a key targeted therapy for breast cancer from Novartis, until now has been indicated only for patients with metastatic disease. But on Tuesday, the Food and Drug Administration approved ...

The U.S. Food and Drug Administration approved Bristol Myers Squibb's schizophrenia drug late on Thursday, making it the ...

Basel, September 17, 2024 – Novartis today announced that the US Food and Drug ... disease-free survival (iDFS) benefit was consistently observed across all patient subgroups 3-6. “The FDA ...

Find out all about the first two FDA drug approvals for the rare genetic disorder Niemann-Pick disease type C.

Women with early stage breast cancer may now take Kisqali, a medication already approved for advanced disease, following the U.S. Food and Drug Administration's expanded approval of the treatment ...

No new treatments for schizophrenia have been approved in nearly three decades, but that changed on Sept. 26, when the U.S. Food and Drug Administration (FDA) approved Cobenfy for the psychiatric ...

17, 2024 /PRNewswire/ -- Novartis today announced that the US Food and Drug ... "The FDA approval of Kisqali for this early breast cancer population, including those with N0 disease, is a pivotal ...

Novartis will continue evaluating NATALEE patients for longer-term outcomes, including overall survival. "With this approval ... effects of prescription drugs to the FDA. Visit www.fda.gov ...